Edition:
United Kingdom

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

11.01USD
16 Feb 2018
Change (% chg)

$0.12 (+1.10%)
Prev Close
$10.89
Open
$10.87
Day's High
$11.21
Day's Low
$10.85
Volume
267,018
Avg. Vol
244,081
52-wk High
$27.07
52-wk Low
$10.53

Select another date:

Mon, Jan 22 2018

BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721

* EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY

BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

BRIEF-Omeros Corp amends term loan agreement

* On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​

BRIEF-OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

* OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

Select another date: